May 2018 in “KU ScholarWorks (The University of Kansas)” Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
61 citations
,
September 2011 in “Pain” PEA reduces pain by increasing neurosteroid synthesis in the spinal cord.
4 citations
,
January 2025 in “International Journal of Molecular Sciences” Progesterone reduces anxiety and depression in female mice by increasing BDNF in the brain, needing 5α-reduction and estradiol.
180 citations
,
June 2004 in “Journal of Pharmacology and Experimental Therapeutics” Progesterone's seizure-reducing effects are mainly due to allopregnanolone, not progesterone receptors.
49 citations
,
January 2010 in “Plant and Cell Physiology” LPR1 regulates root growth under low phosphate stress independently of SIZ1 in Arabidopsis thaliana.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
August 2008 in “European Neuropsychopharmacology” RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
July 2026 in “Frontiers in Endocrinology” PRLR mutations affect cattle growth and hair weight in hot climates.
June 2025 in “International Journal of Nephrology and Renovascular Disease” PLA2R1 overexpression harms kidney cells by stopping their growth cycle.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.
July 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Improved CRBN ligands make protein degraders more effective and drug-like.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
July 2026 in “Journal of Medicinal Chemistry” A new drug strategy improves hair loss treatment with better results and safety.
July 2026 in “Current Issues in Molecular Biology” Plerixafor may help restore skin pigmentation safely.
24 citations
,
August 2017 in “Prostaglandins & Other Lipid Mediators” CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
May 2005 in “Molecular Carcinogenesis” mrp/plf-mRNA can indicate tumor-promoting effects in skin.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
11 citations
,
May 2010 in “Journal of Medicinal Chemistry” A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
29 citations
,
October 2009 in “Pharmacology Biochemistry and Behavior”
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.